Thursday, February 23, 2023 Daily Archives

eBook: Monoclonal Antibodies — Reviewing the Past Year in Design, Engineering, Characterization, Manufacturing, and Formulation

by

Even as advanced therapies and new modalities grab headlines, the monoclonal antibody (MAb) segment of the biopharmaceutical industry continues to perform, bringing needed treatments for emergent infections, rare diseases, and widespread conditions to patients who need help around the world. In fact, MAbs are at the heart of many emerging therapeutics, including bispecifics/multispecifics, antibody fragments, and antibody–drug conjugates (ADCs). But the original molecular class itself still dominates the biopharmaceutical development pipeline and the interest of biotechnology suppliers around the world.…

February 23, 2023

Donaldson buys reagent firm Isolere Bio

by

The acquisition of Isolere aims to position Donaldson to form separation and filtration solutions for emerging genetic-based drugs, says firm. Minneapolis-based filtration firm, Donaldson Company, has bought early-stage biotech firm, Isolere, for an undisclosed fee. Isolere develops IsoTag reagents, which it says have been designed to drastically increase product quality and purity with quicker timelines to advance and enable access to affordable therapies. “With the integral addition of Isolere to our Life Sciences portfolio, Donaldson is positioned to create premier…

February 23, 2023

The key to plugging CGT talent gaps? Tell kids ‘science is cool’

by

Industry must help the next generation embrace science if we are to overcome the lack of talent in the cell and gene therapy sector, say experts. The lack of qualified staff in the life sciences space is well documented, with the cell and gene therapy particularly affected. A McKinsey & Company blog post last year highlighted the issues, as did the Advanced Therapies Week event in Miami, Florida earlier this year, where conversations around the blossoming industry suggested the sector was…

February 23, 2023